Ironwood Pharmaceuticals IncIRWD

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$4.19
Market cap
$692.4M
P/E
5.3x
Revenue (TTM)
$389.3M
Net income
$129.9M
Dividend yield
—
1-year total return
229.9%
Net margin
33.4%
Revenue growth
26.2%
Debt / equity
—

What Ironwood Pharmaceuticals Inc does.

We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.

LINZESS ® (linaclotide), our commercial product, is the first product approved by the United States Food and Drug Administration, or U.S. FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation, or IBS-C, in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation, or CIC, in adults, and functional constipation, or FC, in pediatric patients ages 6-17 years-old. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA® for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$389.5M$413.8M$410.6M$442.7M$351.4M$296.2M
Net income$106.2M$528.4M$175.1M-$1.0B$880,000$24.0M
Free cash flow$167.0M$261.6M$273.6M$183.2M$103.4M$127.0M

More on IRWD.

Figures from Ironwood Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.